2,3-Bis-bromomethyl-6-methoxy-quinoxaline 1,4-dioxide | 36708-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3-Bis-bromomethyl-6-methoxy-quinoxaline 1,4-dioxide
• 英文别名: 2,3-Bis(bromomethyl)-6-methoxy-4-oxidoquinoxalin-1-ium 1-oxide
• CAS: 36708-65-3
• 化学式: C₁₁H₁₀Br₂N₂O₃
• 分子量: 378.02
• InChiKey: HURSFJLOXJGWTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• JP2011037776A
  申请人：——

  公开号：JP2011037776A

  公开（公告）日：2011-02-24
• PHARMACEUTICAL COMPOSITION COMPRISING SUBSTANCE INHIBITING ENZYMATIC ACTIVITY OF PEROXIREDOXIN 2 AS EFFECTIVE INGREDIENT FOR TREATMENT OF COLORECTAL CANCER
  申请人：EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION

  公开号：US20200129508A1

  公开（公告）日：2020-04-30

  The present invention relates to a pharmaceutical composition for treating colorectal cancer including a material inhibiting the enzyme activity of peroxiredoxin 2 as an active ingredient, and more specifically, to a pharmaceutical composition for treating colorectal cancer, which exhibits the effect of reducing colon polyps via increase of active β-catenin degradation by inhibiting the activity of peroxiredoxin 2, based on the mechanism that promotes colorectal tumor by the interaction between peroxiredoxin 2 (PrxII) and tankyrase (TNKS) in an APC-mutant cell.
• [EN] PHARMACEUTICAL COMPOSITION COMPRISING SUBSTANCE INHIBITING ENZYMATIC ACTIVITY OF PEROXIREDOXIN 2 AS EFFECTIVE INGREDIENT FOR TREATMENT OF COLORECTAL CANCER<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UNE SUBSTANCE INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA PEROXYRÉDOXINE 2 EN TANT QUE PRINCIPE ACTIF POUR LE TRAITEMENT DU CANCER COLORECTAL<br/>[KO] 퍼록시레독신 2 의 효소 활성을 억제하는 물질을 유효 성분으로 포함하는 대장암 치료용 약학적 조성물
  申请人：UNIV EWHA IND COLLABORATION

  公开号：WO2019004732A1

  公开（公告）日：2019-01-03

  본 발명은 퍼록시레독신 2 의 효소 활성을 억제하는 물질을 유효 성분으로 함유하는 대장암 치료용 약학적 조성물에 관한 것으로, 보다 상세하게는 APC 돌연변이 세포에서 퍼록시레독신 2(Prx II) 가 탄키라제(Tankyrase, TNKS)와 상호작용하여 대장암 종양을 촉진하는 메커니즘에 기초하여, 퍼록시레독신 2의 활성을 억제함으로서 활성 베타카테닌 분해를 증가시켜 대장 용종을 감소시키는 효과를 나타내는 대장암 치료용 약학적 조성물에 관한 것이다.